Goldman Sachs Downgrades 2seventy bio to Neutral, Announces $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter has downgraded 2seventy bio (NASDAQ:TSVT) from Buy to Neutral and set a price target of $5.
September 13, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has downgraded 2seventy bio to Neutral from Buy and set a price target of $5. This could potentially impact the stock's performance in the short term.
The downgrade from Goldman Sachs, a major financial institution, could potentially lead to a decrease in investor confidence in 2seventy bio, thereby affecting its stock price. The new price target of $5 also suggests a potential decrease in the stock's value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100